The Endocannabinoid System: a New Molecular Target for the Treatment of Tobacco Addiction

Overview

Journal CNS Neurol Disord Drug Targets

Publisher Bentham Science Publishers

Specialties Neurology
Pharmacology

Date 2009 Jan 9

PMID 19128204

Citations 19

Authors

Maria Scherma

Paola Fadda

Bernard Le Foll

Benoit Forget

Walter Fratta

Steven R Goldberg

Gianluigi Tanda

Affiliations

Soon will be listed here.

Abstract

Tobacco addiction is one of the leading preventable causes of mortality in the world and nicotine appears to be the main critical psychoactive component in establishing and maintaining tobacco dependence. Several lines of evidence suggest that the rewarding effects of nicotine, which underlie its abuse potential, can be modulated by manipulating the endocannabinoid system. For example, pharmacological blockade or genetic deletion of cannabinoid CB(1) receptors reduces or eliminates many behavioral and neurochemical effects of nicotine that are related to its addictive potential. This review will focus on the recently published literature about the role of the endocannabinoid system in nicotine addiction and on the endocannabinoid system as a novel molecular target for the discovery of medications for tobacco dependence.

Citing Articles

Neurobiology of Stress-Induced Nicotine Relapse.

Wang X, Chen Y, Dong J, Ge J, Liu X, Liu J Int J Mol Sci. 2024; 25(3).

PMID: 38338760 PMC: 10855331. DOI: 10.3390/ijms25031482.

Enhancing effect of nicotine on electrical field stimulation elicited contractile responses in isolated rabbit bladder straight muscle; the role of cannabinoid and vanilloid receptors.

Ilhan S, Ozturk Fincan G, Okcay Y, Koc D, Askin C, Kibar A Turk J Med Sci. 2023; 52(6):1814-1820.

PMID: 36945969 PMC: 10390188. DOI: 10.55730/1300-0144.5527.

Unraveling the role of cigarette use in neural cannabis cue reactivity in heavy cannabis users.

Kuhns L, Kroon E, Filbey F, Cousijn J Addict Biol. 2020; 26(3):e12941.

PMID: 32761688 PMC: 7862430. DOI: 10.1111/adb.12941.

Gender Differences in the Association between Marijuana and Menthol Cigarette Use among African American Adult Cigarette Smokers.

Montgomery L, Hooper M Subst Use Misuse. 2020; 55(8):1335-1342.

PMID: 32253967 PMC: 7281863. DOI: 10.1080/10826084.2020.1741633.

Chronic nicotine exposure attenuates the effects of Δ -tetrahydrocannabinol on anxiety-related behavior and social interaction in adult male and female rats.

Manwell L, Miladinovic T, Raaphorst E, Rana S, Malecki S, Mallet P Brain Behav. 2019; 9(11):e01375.

PMID: 31583843 PMC: 6851810. DOI: 10.1002/brb3.1375.

References

Sink K, McLaughlin P, Wood J, Brown C, Fan P, Vemuri V . The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology. 2007; 33(4):946-55. PMC: 3711240. DOI: 10.1038/sj.npp.1301476. View

Zimmer A, Zimmer A, Hohmann A, Herkenham M, Bonner T . Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A. 1999; 96(10):5780-5. PMC: 21937. DOI: 10.1073/pnas.96.10.5780. View

Berke J, Hyman S . Addiction, dopamine, and the molecular mechanisms of memory. Neuron. 2000; 25(3):515-32. DOI: 10.1016/s0896-6273(00)81056-9. View

Meyers A, Klesges R, Winders S, Ward K, Peterson B, Eck L . Are weight concerns predictive of smoking cessation? A prospective analysis. J Consult Clin Psychol. 1997; 65(3):448-52. DOI: 10.1037//0022-006x.65.3.448. View

Hanus L, Fride E, Breuer A, Vogel Z, Shalev D, Kustanovich I . 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A. 2001; 98(7):3662-5. PMC: 31108. DOI: 10.1073/pnas.061029898. View

Price M, Baillie G, Thomas A, Stevenson L, Easson M, Goodwin R . Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005; 68(5):1484-95. DOI: 10.1124/mol.105.016162. View

Cossu G, Ledent C, Fattore L, Imperato A, Bohme G, Parmentier M . Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res. 2001; 118(1):61-5. DOI: 10.1016/s0166-4328(00)00311-9. View

Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G . Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther. 2004; 313(1):352-8. DOI: 10.1124/jpet.104.078980. View

Mansvelder H, McGehee D . Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron. 2000; 27(2):349-57. DOI: 10.1016/s0896-6273(00)00042-8. View

10.

Shalev U, Grimm J, Shaham Y . Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev. 2002; 54(1):1-42. DOI: 10.1124/pr.54.1.1. View

11.

Champtiaux N, Gotti C, Cordero-Erausquin M, David D, Przybylski C, Lena C . Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci. 2003; 23(21):7820-9. PMC: 6740613. View

12.

Pidoplichko V, Debiasi M, Williams J, Dani J . Nicotine activates and desensitizes midbrain dopamine neurons. Nature. 1997; 390(6658):401-4. DOI: 10.1038/37120. View

13.

Rose J . Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl). 2005; 184(3-4):274-85. DOI: 10.1007/s00213-005-0250-x. View

14.

Picciotto M . Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci. 2003; 24(9):493-9. DOI: 10.1016/S0165-6147(03)00230-X. View

15.

Butt C, Alptekin A, Shippenberg T, Oz M . Endogenous cannabinoid anandamide inhibits nicotinic acetylcholine receptor function in mouse thalamic synaptosomes. J Neurochem. 2008; 105(4):1235-43. DOI: 10.1111/j.1471-4159.2008.05225.x. View

16.

Scherma M, Panlilio L, Fadda P, Fattore L, Gamaleddin I, Le Foll B . Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther. 2008; 327(2):482-90. PMC: 2663803. DOI: 10.1124/jpet.108.142224. View

17.

Solinas M, Scherma M, Tanda G, Wertheim C, Fratta W, Goldberg S . Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. J Pharmacol Exp Ther. 2007; 321(3):1127-34. DOI: 10.1124/jpet.106.116830. View

18.

Kaprio J, Hammar N, Koskenvuo M, Floderus-Myrhed B, Langinvainio H, Sarna S . Cigarette smoking and alcohol use in Finland and Sweden: a cross-national twin study. Int J Epidemiol. 1982; 11(4):378-86. DOI: 10.1093/ije/11.4.378. View

19.

Grottick A, Wyler R, Higgins G . The alpha4beta2 agonist SIB 1765F, but not the alpha7 agonist AR-R 17779, cross-sensitises to the psychostimulant effects of nicotine. Psychopharmacology (Berl). 2000; 150(2):233-6. DOI: 10.1007/s002130000444. View

20.

Le Foll B, George T . Treatment of tobacco dependence: integrating recent progress into practice. CMAJ. 2007; 177(11):1373-80. PMC: 2072983. DOI: 10.1503/cmaj.070627. View